Investment
Features
FeesSafety
Academy
More
Pluang+

Compare HCA Health Inc (HCA) vs Altria Group Inc (MO) Price & Performance

HCA Health IncTrade
Altria Group IncTrade

Price performance (Past 24H)

Key statistics

HCA Health Inc vs Altria Group Inc — how do they compare? HCA Health Inc trades at $411.81 (market cap $89.64B), while Altria Group Inc trades at $64.93 (market cap $114.13B). The key difference: Altria Group Inc is the larger of the two by market cap, and Altria Group Inc pays the higher dividend (6.2%). Which is the better fit depends on your goals.

HCAMO
Market Cap
$89.64B$114.13B
Sector
HealthConsumer Staples
52-Week High
$545.13$74.92
52-Week Low
$361.32$54.72
Enterprise Value
$140.18B$136.34B
Dividend Yield
0.75%6.2%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

HCA Health Inc

HCA Healthcare trades at $413.36, up 1.09% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $449.93. The company reported strong Q2 2026 earnings of $7.59 per share, beating estimates, and has shown consistent revenue growth, reaching $75.60 billion in 2025. Recent corporate actions include dividend payments of $0.78 per share, while news highlights executive appointments and ongoing legal investigations.

The stock presents a compelling investment case with attractive valuation multiples like a P/E of 13.86 and robust profitability, but faces risks from legal probes and high debt levels. Upside potential is supported by analyst optimism and solid operational cash flow, though investors should monitor expense pressures and regulatory developments.

Altria Group Inc

Altria Group (MO) trades at $68.35, up 0.89% with mixed technical signals showing bearish moving averages but oversold RSI levels. The company maintains strong profitability with 39% net income margin and $6.95B net income for 2025, though revenue declined slightly to $20.14B. Recent earnings show alternating beats and misses, with Q3 2026 results pending. Analyst consensus remains bullish with 61.5% buy ratings and $71.50 price target, while the stock offers a 6.3% dividend yield with 56 consecutive annual increases expected.

MO presents value opportunity with 14.4x P/E ratio and strong cash flow generation, but faces headwinds from cigarette volume declines and regulatory pressures. The smoke-free product transition shows progress but remains early stage. Current price near support at $67 suggests limited downside, while analyst targets indicate 4.6% upside potential. Key risks include litigation exposure and slower-than-expected diversification from traditional tobacco products.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About HCA Health Inc

HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.

Read more on HCA

About Altria Group Inc

Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).

Read more on MO